Skip to content

Randomized controlled double-blind clinical study for oral magnesium threonate (L-TAMS) to prevent cognitive/affective disorders and postoperative pain caused by radical mastectomy and chemotherapy

Randomized controlled double-blind clinical study for oral magnesium threonate (L-TAMS) to prevent cognitive/affective disorders and postoperative pain caused by radical mastectomy and chemotherapy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023820
Enrollment
Unknown
Registered
2019-06-13
Start date
2019-06-11
Completion date
Unknown
Last updated
2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive/affective disorders and postoperative pain caused by radical mastectomy and chemotherapy

Interventions

test group:Oral magnesium threonate

Sponsors

The Third Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
17 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18 to 70 years,woman, VAS score <7 points; 2) Breast cancer is planned for breast cancer surgery and patients undergoing postoperative chemotherapy; 3) With the approval of the hospital ethics committee, the patient volunteers and signs the informed consent form; 4) Subjects can objectively describe the symptoms and follow the product dose and visit plan; 5) The expected survival period is more than 6 months.

Exclusion criteria

Exclusion criteria: 1) Pregnant or lactating women; 2) History of chronic pain, drug addiction and history of mental illness; 3) Suffering from severe respiratory system, cardiovascular disease, liver and kidney dysfunction, immune system diseases and other tumors; 4) Analgesics, antiepileptics, antidepressants, and drugs that affect Mg metabolism (thiazine diuretics, loop diuretics, magnesium antacids, calcium channel blockers, penicillamine, cortex) Hormone, etc.) 5) Those suffering from allergic diseases, allergic to the body; those who are allergic to magnesium threonate products; 6) Patients who participated in any randomized controlled product trials within 3 months prior to the trial (including the trial product); 7) Sponsors or researchers or their family members who are directly involved in the trial; 8) The investigator believes that there is a reason for not being selected.

Design outcomes

Primary

MeasureTime frame
Cognitive function assessment;

Secondary

MeasureTime frame
Sitting experiment;Plasma Mg2+ concentration;Quality of life assessment;Pain assessment;Mental and psychological factors assessment;

Countries

China

Contacts

Public ContactDong Huang

The Third Xiangya Hospital of Central South University

huangdong6619@vip.163.com+86 13787412741

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026